Genetic Determinants of Pemetrexed Responsiveness and Nonresponsiveness in Non-small Cell Lung Cancer Cells
- 1 August 2010
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 5 (8) , 1143-1151
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- YNK1, the yeast homolog of human metastasis suppressor NM23, is required for repair of UV radiation- and etoposide-induced DNA damageMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Emerging drugs for mesotheliomaExpert Opinion on Emerging Drugs, 2007
- Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosisLeukemia, 2007
- Role of Pemetrexed in Non-Small Cell Lung CancerCancer Investigation, 2007
- The Metastasis Suppressor NM23-H1 Possesses 3′-5′ Exonuclease ActivityJournal of Biological Chemistry, 2004
- Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell lineBiochemical Pharmacology, 2003
- Loss of folylpoly‐γ‐glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation‐dependent novel antifolates in multiple human leukemia sublinesInternational Journal of Cancer, 2002
- Experimentally determined lipocalin structuresBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinomaBritish Journal of Cancer, 1999